Serum bioactive parathyroid hormone in hemodialysis patients

James T. McCarthy, George G. Klee, Pai Chih Kao, Stephen F. Hodgson

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


In 41 hemodialysis patients with bone disease (histological diagnosis with histomorphometric confirmation of PTH activity) results from a serum immunoreactive PTH (iPTH) assay correlated with results from a new serum bioactive PTH (bio-PTH) assay (r = 0.84; P < 0.001). The serum bio-PTH values correlated well with osteoclast numbers (r = 0.70; P < 0.001), resorption surfaces (r = 0.55; P < 0.001), and presence of marrow fibrosis (P < 0.02). The serum iPTH values also correlated with osteoclast numbers (r = 0.61; P < 0.001), resorption surfaces (r = 0.47; P < 0.003), and presence of marrow fibrosis (P < 0.02). Serum bio-PTH and iPTH values were higher in patients with severe hyperparathyroidism than in other patients. The assays were equally useful in identifying dialysis patients with severe hyperparathyroidism. Patients with osteomalacia or low turnover bone disease had low serum bio-PTH and/or iPTH values. Low bio-PTH values (≤3.6 pmol/L) had a sensitivity and a specificity of 93% for osteomalacia or low turnover bone disease. Low bio-PTH values also were useful in identifying those patients with positive aluminum staining in bone. The serum bio-PTH assay was useful in identifying patients with osteomalacia, low turnover bone disease, or aluminum accumulation.

Original languageEnglish (US)
Pages (from-to)340-345
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Issue number2
StatePublished - Feb 1989

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Serum bioactive parathyroid hormone in hemodialysis patients'. Together they form a unique fingerprint.

Cite this